Single H5N1 influenza A neuraminidase mutation develops resistance to oseltamivir due to distorted conformational and drug binding landscape: Multiple molecular dynamics analyses

RSC Advances

Volumn 5, Issue 14, 2015, Pages 10849-10861

  Mhlongo, Ndumiso N ^a   Soliman, Mahmoud E S ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; FREE ENERGY; HYDROGEN BONDS; MOLECULAR DYNAMICS; VIRUSES;

ATOMIC INTERACTIONS; BINDING FREE ENERGY; HYDROGEN BONDING NETWORK; MOLECULAR MECHANISM; NEURAMINIDASE INHIBITORS; OSELTAMIVIR RESISTANCES; SECONDARY STRUCTURES; SOLVENT ACCESSIBLE SURFACE AREAS;

PRINCIPAL COMPONENT ANALYSIS;

EID: 84921658357     PISSN: None     EISSN: 20462069     Source Type: Journal    
DOI: 10.1039/c4ra13494j     Document Type: Article

References (51)

1. E. A. Govorkova, N. A. Ilyushina, J. L. McClaren, T. S. P. Naipospos, B. Douangngeun and R. G. Webster, Susceptibility of Highly Pathogenic H5N1 Influenza Viruses to the Neuraminidase Inhibitor Oseltamivir Differs In Vitro and in a Mouse Model, Antimicrob. Agents Chemother., 2009, 53, 3088-3096.
2. E. A. Govorkova, T. Baranovich, P. Seiler, J. Armstrong, A. Burnham, Y. Guan, M. Peiris, R. J. Webby and R. G. Webster, Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring, Antiviral Res., 2013, 98, 297-304.
3. R. J. Russell, L. F. Haire, D. J. Stevens, P. J. Collins, Y. P. Lin, G. M. Blackburn, A. J. Hay, S. J. Gamblin and J. J. Skehel, The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design, Nature, 2006, 443, 45-49.
4. S. Q. Wang, Q. S. Du and K. C. Chou, Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases, Biochem. Biophys. Res. Commun., 2007, 354, 634-640.
5. D. J. Bucher and E. Kilbourn, A2 (N2) Neuraminidase of X-7 Influenza-virus recombinant - Determination of molecular-size and subunit composition of active unit, J. Virol., 1972, 10, 60-66.
6. J. L. McKimm-Breschkin, P. W. Selleck, T. B. Usman and M. A. Johnson, Reduced sensitivity of influenza A (H5N1) to oseltamivir, Emerging Infect. Dis., 2007, 13, 1354-1357.
7. L. V. Gubareva, L. Kaiser and F. G. Hayden, Influenza virus neuraminidase inhibitors, Lancet, 2000, 355, 827-835.
8. M. D. de Jong, T. T. Thanh, T. H. Khanh, V. M. Hien, G. J. D. Smith, N. V. Chau, B. V. Cam, P. T. Qui, D. Q. Ha, Y. Guan, J. S. M. Peiris, T. T. Hien and J. Farrar, Brief report - Oseltamivir resistance during treatment of influenza A (H5N1) infection, N. Engl. J. Med., 2005, 353, 2667-2672.
9. C. U. Kim, W. Lew, M. A. Williams, H. T. Liu, L. J. Zhang, S. Swaminathan, N. Bischofberger, M. S. Chen, D. B. Mendel, C. Y. Tai, W. G. Laver and R. C. Stevens, Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity, J. Am. Chem. Soc., 1997, 119, 681-690.
10. Y. Matsuzaki, K. Mizuta, Y. Aoki, A. Suto, C. Abiko, K. Sanjoh, K. Sugawara, E. Takashita, T. Itagaki, Y. Katsushima, M. Ujike, M. Obuchi, T. Odagiri and M. Tashiro, A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir, Virol. J., 2010, 7, 53.
11. N. J. Dharan, L. V. Gubareva, J. J. Meyer, M. Okomo- Adhiambo, R. C. McClinton, S. A. Marshall, K. S. George, S. Epperson, L. Brammer, A. I. Klimov, J. S. Bresee and A. M. Fry, Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States, JAMA, J. Am. Med. Assoc., 2009, 301, 1034-1041.
12. J. L. McKimm-Breschkin, Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance, Influenza Other Respir. Viruses, 2013, 7, 25-36.
13. R. Takano, M. Kiso, M. Igarashi, L. Quynh Mai, M. Sekijima, K. Ito, A. Takada and Y. Kawaoka, Molecular Mechanisms Underlying Oseltamivir Resistance Mediated by an I117V Substitution in the Neuraminidase of Subtype H5N1 Avian Influenza A Viruses, J. Infect. Dis., 2013, 207, 89-97.
14. M. Z. Wang, C. Y. Tai and D. B. Mendel, Mechanism by which mutations at His274 alter sensitivity of influenza a virus N1 neuraminidase to oseltamivir carboxylate and zanamivir, Antimicrob. Agents Chemother., 2002, 46, 3809-3816.
15. M. A. Rameix-Welti, F. Agou, P. Buchy, S. Mardy, J. T. Aubin, M. Veron, S. van der Werf and N. Naffakh, Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir, Antimicrob. Agents Chemother., 2006, 50, 3809-3815.
16. A. Moscona, Drug therapy - Neuraminidase inhibitors for influenza, N. Engl. J. Med., 2005, 353, 1363-1373.
17. N. Renzette, D. R. Caffrey, K. B. Zeldovich, P. Liu, G. R. Gallagher, D. Aiello, A. J. Porter, E. A. Kurt-Jones, D. N. Bolon, Y.-P. Poh, J. D. Jensen, C. A. Schiffer, T. F. Kowalik, R. W. Finberg and J. P. Wang, Evolution of the Influenza A Virus Genome during Development of Oseltamivir Resistance In Vitro, J. Virol., 2014, 88, 272-281.
18. M. L. Mihajlovic and P. M. Mitrasinovic, Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV), Biophys. Chem., 2008, 136, 152-158.
19. A. C. Hurt, P. Selleck, N. Komadina, R. Shaw, L. Brown and I. G. Barr, Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes, Antiviral Res., 2007, 73, 228-231.
20. C. J. Woods, M. Malaisree, B. Long, S. McIntosh-Smith and A. J. Mulholland, Analysis and Assay of Oseltamivir-Resistant Mutants of Influenza Neuraminidase via Direct Observation of Drug Unbinding and Rebinding in Simulation, Biochemistry, 2013, 52, 8150-8164.
21. F. S. Legge, A. Budi, H. Treutlein and I. Yarovsky, Protein flexibility: multiple molecular dynamics simulations of insulin chain B, Biophys. Chem., 2006, 119, 146-157.
22. J. P. Ma and M. Karplus, Molecular switch in signal transduction: reaction paths of the conformational changes in ras p21, Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 11905-11910.
23. J. Apostolakis, P. Ferrara and A. Caflisch, Calculation of conformational transitions and barriers in solvated systems: application to the alanine dipeptide in water, J. Chem. Phys., 1999, 110, 2099-2108.
24. M. Karplus and A. Sali, Theoretical studies of protein-folding and unfolding, Curr. Opin. Struct. Biol., 1995, 5, 58-73.
25. L. Yang, G. Song, A. Carriquiry and R. L. Jernigan, Close correspondence between the motions from principal component analysis of multiple HIV-1 protease structures and elastic network modes, Structure, 2008, 16, 321-330.
26. A. Amadei, A. B. M. Linssen and H. J. C. Berendsen, Essential dynamics of proteins, Proteins: Struct., Funct., Genet., 1993, 17, 412-425.
27. D. M. F. vanAalten, J. B. C. Findlay, A. Amadei and H. J. C. Berendsen, Essential dynamics of the cellular retinol-binding protein - evidence for ligand-induced conformational changes, Protein Eng., 1995, 8, 1129-1135.
28. S. Bhakat, A. J. M. Martin and M. E. S. Soliman, An integrated molecular dynamics, principal component analysis and residue interaction network approach reveals the impact of M184V mutation on HIV reverse transcriptase resistance to lamivudine, Mol. BioSyst., 2014, 10, 2215-2228.
29. E. Laine, I. C. de Beauchene, D. Perahia, C. Auclair and L. Tchertanov, Mutation D816V Alters the Internal Structure and Dynamics of c-KIT Receptor Cytoplasmic Region: Implications for Dimerization and Activation Mechanisms, PLoS Comput. Biol., 2011, 7, 1-20.
30. E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng and T. E. Ferrin, UCSF chimera - a visualization system for exploratory research and analysis, J. Comput. Chem., 2004, 25, 1605-1612.
31. M. D. Hanwell, D. E. Curtis, D. C. Lonie, T. Vandermeersch, E. Zurek and G. R. Hutchison, Avogadro: an advanced semantic chemical editor, visualization, and analysis platform, J. Cheminf., 2012, 4, 17-33.
32. A. W. Goetz, M. J. Williamson, D. Xu, D. Poole, S. Le Grand and R. C. Walker, Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 1. Generalized Born, J. Chem. Theory Comput., 2012, 8, 1542-1555.
33. R. Salomon-Ferrer, A. W. Goetz, D. Poole, S. Le Grand and R. C. Walker, Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald, J. Chem. Theory Comput., 2013, 9, 3878-3888.
34. K. Lindorff-Larsen, S. Piana, K. Palmo, P. Maragakis, J. L. Klepeis, R. O. Dror and D. E. shaw, Improved side-chain torsion potentials for the Amber ff99SB protein force field, Proteins: Struct., Funct., Bioinf., 2010, 78, 1950-1958.
35. W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, R. W. Impey and M. L. Klein, Comparison of simple potential functions for simulating liquid water, J. Chem. Phys., 1983, 79, 926-935.
36. K. Kholmurodov, W. Smith, K. Yasuoka, T. Darden and T. Ebisuzaki, A smooth-particle mesh Ewald method for DL-POLY molecular dynamics simulation package on the Fujitsu VPP700, J. Comput. Chem., 2000, 21, 1187-1191.
37. P. Gonnet, P-SHAKE: a quadratically convergent SHAKE in O(n(2)), J. Comput. Phys., 2007, 220, 740-750.
38. S. Le Grand, A. W. Goetz and R. C. Walker, SPFP: Speed without compromise-a mixed precision model for GPU accelerated molecular dynamics simulations, Comput. Phys. Commun., 2013, 184, 374-380.
39. H. J. C. Berendsen, J. P. M. Postma, W. F. Vangunsteren, A. Dinola and J. R. Haak, Molecular-dynamics with coupling to an external bath, J. Chem. Phys., 1984, 81, 3684-3690.
40. D. R. Roe and T. E. Cheatham III, PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data, J. Chem. Theory Comput., 2013, 9, 3084-3095.
41. P. A. Kollman, I. Massova, C. Reyes, B. Kuhn, S. H. Huo, L. Chong, M. Lee, T. Lee, Y. Duan, W. Wang, O. Donini, P. Cieplak, J. Srinivasan, D. A. Case and T. E. Cheatham, Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models, Acc. Chem. Res., 2000, 33, 889-897.
42. I. Massova and P. A. Kollman, Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding, Perspect. Drug Discovery Des., 2000, 18, 113-135.
43. V. Tsui and D. A. Case, Theory and applications of the generalized Born solvation model in macromolecular simulations, Biopolymers, 2000, 56, 275-291.
44. A. Onufriev, D. Bashford and D. A. Case, Modification of the generalized Born model suitable for macromolecules, J. Phys. Chem. B, 2000, 104, 3712-3720.
45. T. Hou, J. Wang, Y. Li and W. Wang, Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations, J. Chem. Inf. Model., 2011, 51, 69-82.
46. L. Xu, H. Sun, Y. Li, J. Wang and T. Hou, Assessing the Performance of MM/PBSA and MM/GBSA Methods. 3. The Impact of Force Fields and Ligand Charge Models, J. Phys. Chem. B, 2013, 117, 8408-8421.
47. D. R. Roe and T. E. Cheatham III, PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data, J. Chem. Theory Comput., 2013, 9, 3084-3095.
48. W. Humphrey, A. Dalke and K. Schulten, VMD: visual molecular dynamics, J. Mol. Graphics Modell., 1996, 14, 33-38.
49. A. Bakan, L. M. Meireles and I. Bahar, ProDy: Protein Dynamics Inferred from Theory and Experiments, Bioinformatics, 2011, 27, 1575-1577.
50. V. Karthick and K. Ramanathan, Insight into the Oseltamivir Resistance R292K Mutation in H5N1 Influenza Virus: A Molecular Docking and Molecular Dynamics Approach, Cell Biochem. Biophys., 2014, 68, 291-299.
51. A. C. Hurt, S. K. Leang, D. J. Speers, I. G. Barr and S. Maurer-Stroh, Mutations I117V and I117M and Oseltamivir Sensitivity of Pandemic (H1N1) 2009 Viruses, Emerging Infect. Dis., 2012, 18, 109-112.